Education
About Us
Working with TipRanks
Follow Us
Neurogene (NGNE)
NASDAQ:NGNE
NGNE Stock Chart & Stats
Day’s Range― - ―
52-Week Range$6.88 - $74.49
Previous CloseN/A
Volume20.02K
Average Volume (3M)117.61K
Market Cap
$285.72M
Enterprise Value$51.22M
Total Cash (Recent Filing)$274.52M
Total Debt (Recent Filing)$10.97M
Price to Earnings (P/E)―
Beta2.96
Next Earnings
Nov 24, 2025EPS Estimate
-1.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.05
Shares Outstanding14,271,916
10 Day Avg. Volume128,468
30 Day Avg. Volume117,605
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.18
Enterprise Value/Revenue-55.38
Enterprise Value/Gross Profit-16.09
Enterprise Value/Ebitda-0.63
Forecast
1Y Price Target
$46.75Price Target Upside137.31% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressNeurogene announced pivotal trial design appears to offer a clear path to show a benefit for Rett patients treated with NGN-401.
Financial PlanningCash reserves at the end of the period were $274.5M, expected to provide financial runway into early 2028, indicating strong financial planning.
Safety ProfileNo cases of hemophagocytic lymphohistiocytosis (HLH) or hyperinflammatory syndrome have been observed in the 10 patients treated at the 1E15 vg dose level, indicating a favorable safety profile.
Bears Say
Earnings OutlookModestly increase R&D for pivotal costs and nudge EU/RoW launch to 2030 as clarity on OUS regulatory pathway is awaited, decreasing the PT to $70.
Financial StabilityThe net loss reported was $22M, which could be a concern for financial stability.
Regulatory ChallengesThe FDA advised that a 6-month endpoint would not be considered clinically meaningful, requiring the study to focus on a 12-month primary endpoint.
Neurogene News
NGNE FAQ
What was Neurogene’s price range in the past 12 months?
Neurogene lowest stock price was $6.88 and its highest was $74.49 in the past 12 months.
What is Neurogene’s market cap?
Neurogene’s market cap is $285.72M.
When is Neurogene’s upcoming earnings report date?
Neurogene’s upcoming earnings report date is Nov 24, 2025 which is in 88 days.
How were Neurogene’s earnings last quarter?
Neurogene released its earnings results on Aug 11, 2025. The company reported -$1.05 earnings per share for the quarter, beating the consensus estimate of -$1.16 by $0.11.
Is Neurogene overvalued?
According to Wall Street analysts Neurogene’s price is currently Undervalued.
Does Neurogene pay dividends?
Neurogene does not currently pay dividends.
What is Neurogene’s EPS estimate?
Neurogene’s EPS estimate is -1.25.
How many shares outstanding does Neurogene have?
Neurogene has 14,271,916 shares outstanding.
What happened to Neurogene’s price movement after its last earnings report?
Neurogene reported an EPS of -$1.05 in its last earnings report, beating expectations of -$1.16. Following the earnings report the stock price went down -5.553%.
Which hedge fund is a major shareholder of Neurogene?
Currently, no hedge funds are holding shares in NGNE
Neurogene Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$46.75 (137.31% Upside)
$46.75 (137.31% Upside)
Blogger Sentiment
Bullish
NGNE Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 953.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.7%
Last 30 Days ▼ 3.4%
Last 30 Days ▼ 3.4%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-45.52%
12-Months-Change
Fundamentals
Return on Equity
-39.41%
Trailing 12-Months
Asset Growth
65.34%
Trailing 12-Months
Company Description
Neurogene
Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York.
NGNE Stock 12 Month Forecast
Average Price Target
$46.75
▲(137.31% Upside)
Technical Analysis
ProQR
―
Korro Bio
―
Inhibikase Therapeutics
―
4D Molecular Therapeutics
―
Lyell Immunopharma
―
Ownership Overview
21.83% Insiders
12.06% Mutual Funds
<0.01% Other Institutional Investors
56.70% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---